Pharmacology of AMPA/kainate receptor ligands and their therapeutic potential in neurological and psychiatric disorders.
about
Neuroprotection for ischemic stroke: past, present and futureThe amygdala is not necessary for unconditioned stimulus inflation after Pavlovian fear conditioning in rats.Targeting α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors in epilepsy.Attenuation of AMPA receptor activity improves motor skills in a mouse model of juvenile Batten disease.Structure and function of AMPA receptors.Hypoxia regulates glutamate receptor trafficking through an HIF-independent mechanismRole of Paraventricular Nucleus Glutamate Signaling in Regulation of HPA Axis Stress Responses.Glutamatergic neurotransmission modulators as emerging new drugs for schizophrenia.The p38 MAP kinase pathway modulates the hypoxia response and glutamate receptor trafficking in aging neuronsNBQX, a highly selective competitive antagonist of AMPA and KA ionotropic glutamate receptors, increases seizures and mortality following picornavirus infectionClassifying neuronal subclasses of the cerebellum through constellation pharmacology.Medicinal chemistry of competitive kainate receptor antagonists.New AMPA antagonists in epilepsy.Perampanel, a novel, non-competitive, selective AMPA receptor antagonist as adjunctive therapy for treatment-resistant partial-onset seizures.Pharmaceuticals that contain polycyclic hydrocarbon scaffolds.Glutamate is a positive autocrine signal for glucagon release.Pair wise binding affinity: 3D QSAR studies on a set of triazolo [1, 5-a] quinoxalines as antagonists of AMPA and KA receptors.Coantagonism of glutamate receptors and nicotinic acetylcholinergic receptors disrupts fear conditioning and latent inhibition of fear conditioning.Alterations in behaviour and glutamate transmission following presentation of stimuli previously associated with cocaine exposure.CoCl2-induced biochemical hypoxia down regulates activities and expression of super oxide dismutase and catalase in cerebral cortex of mice.Selective blockade of A(2A) receptor protects against neurotoxicity induced by kainic acid in young rats.Synaptic regulation of somatodendritic dopamine release by glutamate and GABA differs between substantia nigra and ventral tegmental area.Activation of Ca-permeable Kainate Receptor3D-QSAR studies for the binding affinity toward (R, S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)-propionic acid receptor.1,2,4-Benzothiadiazine-1,1-dioxide derivatives as ionotropic glutamate receptor ligands: synthesis and structure-activity relationships.Recent developments on triazole nucleus in anticonvulsant compounds: a review.New trends in the development of AMPA receptor antagonists
P2860
Q24645185-3A165FD7-CCEC-4A88-8E21-0438817CBAB8Q30479395-E0A56319-DB95-44AA-888E-98D9F3A416FFQ34395565-5A51D019-3A87-411D-9F2C-E0F461B72161Q34707128-C1A2B2C8-8EC7-4AD1-892E-4AE22A08333FQ35596486-B9D12E37-FE68-43B6-B87D-20679B39A92AQ35874934-1AF4376A-C19F-4F6F-8CBD-6FD47A6B02ECQ36156487-818BF749-121D-4F5D-9F98-90C5A621734FQ36302850-CFF33445-ED9F-43E5-B539-C66FE01ABD1AQ36642175-03593754-462B-48AF-99F1-CE034D2897B9Q36880171-7A548034-7DE1-489E-A0F8-90991EB264A6Q36956308-CF95C467-DC13-453D-B6AA-E8F9409CD250Q38025106-7DA21869-57B5-4E3B-8D50-56634FCBB43FQ38025721-9F291223-C641-4D7E-B0F7-A5375D64FC45Q38069246-96CFB2F4-3CBA-408B-83EF-4C67A04C1FCFQ38546598-133788A4-8C46-4998-9203-CD1518801BDEQ39628842-7C8544D0-D8CE-4859-B9DA-81005D1171E0Q39968685-65B80B66-20BD-4DBC-A80D-EA83D5CE2B48Q41842706-D57308A6-9B04-4613-84F9-0F95BA1CE5FFQ42517807-D611ED28-795E-4451-9572-E5EFE1349EC9Q43442104-245DC39F-8CDF-4EB1-BE68-CA431531702FQ43556088-DEDC6C86-9E4A-4EE0-A39B-349FC65EEA51Q44029775-A1C1CC97-11A1-4A56-B73F-5219F92B9F70Q45317828-12A4A41D-0AA2-4C7E-9107-D5DAAC0D0E9DQ46185875-5E0E4D13-0DE0-453D-85BA-7CC86D1486F3Q48554832-817D2F1B-C3C0-4D53-A503-8E4794921CF3Q49564600-813A7D31-80E1-477C-ABEA-9E1D4180B093Q59070865-EFF28F1A-BEC3-42FB-B456-409986BCCB51
P2860
Pharmacology of AMPA/kainate receptor ligands and their therapeutic potential in neurological and psychiatric disorders.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Pharmacology of AMPA/kainate r ...... cal and psychiatric disorders.
@ast
Pharmacology of AMPA/kainate r ...... cal and psychiatric disorders.
@en
type
label
Pharmacology of AMPA/kainate r ...... cal and psychiatric disorders.
@ast
Pharmacology of AMPA/kainate r ...... cal and psychiatric disorders.
@en
prefLabel
Pharmacology of AMPA/kainate r ...... cal and psychiatric disorders.
@ast
Pharmacology of AMPA/kainate r ...... cal and psychiatric disorders.
@en
P2860
P1433
P1476
Pharmacology of AMPA/kainate r ...... cal and psychiatric disorders.
@en
P2093
P2860
P356
10.2165/00003495-200059010-00004
P577
2000-01-01T00:00:00Z
P6179
1052264758